{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:16:17Z","timestamp":1764494177483,"version":"3.40.5"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Treatment of drug-resistant tuberculosis (TB), which is usually less successful than that of drug-susceptible TB, represents a challenge for TB control and elimination. We aimed to evaluate treatment outcomes and to identify the factors associated with death among patients with MDR and XDR-TB in Portugal. We assessed MDR-TB cases reported for the period 2000\u20132016, using the national TB Surveillance System. Treatment outcomes were defined according to WHO recommendations. We identified the factors associated with death using logistic regression. We evaluated treatment outcomes of 294 MDR- and 142 XDR-TB patients. The treatment success rate was 73.8% among MDR- and 62.7% among XDR-TB patients (p = 0.023). The case-fatality rate was 18.4% among MDR- and 23.9% among XDR-TB patients. HIV infection (OR 4.55; 95% CI 2.31\u20138.99; <jats:italic>p<\/jats:italic> &lt; 0.001) and resistance to one or more second-line injectable drugs (OR 2.73; 95% CI 1.26\u20135.92; <jats:italic>p<\/jats:italic> = 0.011) were independently associated with death among MDR-TB patients. HIV infection, injectable drug use, past imprisonment, comorbidities, and alcohol abuse are conditions that were associated with death early on and during treatment. Early diagnosis of MDR-TB and further monitoring of these patients are necessary to improve treatment outcome.<\/jats:p>","DOI":"10.1371\/journal.pone.0250028","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T17:48:46Z","timestamp":1618940926000},"page":"e0250028","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of drug-resistant tuberculosis treatment outcome in Portugal, 2000\u20132016"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1306-5009","authenticated-orcid":true,"given":"Olena","family":"Oliveira","sequence":"first","affiliation":[]},{"given":"Rita","family":"Gaio","sequence":"additional","affiliation":[]},{"given":"Margarida","family":"Correia-Neves","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8374-6347","authenticated-orcid":true,"given":"Teresa","family":"Rito","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Duarte","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"pone.0250028.ref001","unstructured":"WHO. Global Tuberculosis Report 2019. Geneva, Switzerland: 2019."},{"key":"pone.0250028.ref002","unstructured":"ECD\/WHO. Tuberculosis surveillance and monitoring in Europe 2020\u20132018 date. Stockholm, Sweden: 2020."},{"key":"pone.0250028.ref003","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ijid.2020.01.042","article-title":"MDR\/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network","volume":"92s","author":"GB Migliori","year":"2020","journal-title":"International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases"},{"key":"pone.0250028.ref004","unstructured":"WHO. Best practices in prevention, control and care for drug-resistant tuberculosis. Geneva, Switzerland: 2013."},{"key":"pone.0250028.ref005","unstructured":"WHO. Compendium of good practices in the implementation of the Tuberculosis Action Plan for the WHO European Region 2016\u20132020. Geneva, Switzerland: 2019."},{"key":"pone.0250028.ref006","unstructured":"ARS LVT. Plano Regional de Sa\u00fade 2013\u20132016. Anexos. Lisboa, ARS LVT: 2013."},{"issue":"1","key":"pone.0250028.ref007","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1183\/09031936.00188313","article-title":"Management of patients with multidrug-resistant\/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement","volume":"44","author":"C Lange","year":"2014","journal-title":"Eur Respir J"},{"issue":"3","key":"pone.0250028.ref008","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"D Falzon","year":"2017","journal-title":"Eur Respir J"},{"issue":"6","key":"pone.0250028.ref009","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1183\/09031936.00197912","article-title":"Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal","volume":"42","author":"O Oliveira","year":"2013","journal-title":"Eur Respir J"},{"issue":"Rr-14","key":"pone.0250028.ref010","first-page":"1","article-title":"Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings","volume":"55","author":"BM Branson","year":"2006","journal-title":"MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports"},{"volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis","year":"2008","author":"WHO","key":"pone.0250028.ref011"},{"volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis\u2013 2011 update","year":"2011","author":"WHO","key":"pone.0250028.ref012"},{"volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","year":"2019","author":"WHO","key":"pone.0250028.ref013"},{"volume-title":"Definitions and reporting framework for tuberculosis\u2013 2013 revision","year":"2013","author":"WHO","key":"pone.0250028.ref014"},{"key":"pone.0250028.ref015","unstructured":"WHO. Tuberculosis action plan for the WHO European Region 2016\u20132020. 2015."},{"issue":"3","key":"pone.0250028.ref016","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00803-2016","article-title":"An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis","volume":"49","author":"ML Bastos","year":"2017","journal-title":"Eur Respir J"},{"issue":"1","key":"pone.0250028.ref017","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12879-019-4211-0","article-title":"Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres","volume":"19","author":"N Riccardi","year":"2019","journal-title":"BMC infectious diseases"},{"key":"pone.0250028.ref018","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13756-019-0561-z","article-title":"Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005\u20132015","volume":"8","author":"IS Pradipta","year":"2019","journal-title":"Antimicrobial resistance and infection control"},{"issue":"11","key":"pone.0250028.ref019","doi-asserted-by":"crossref","first-page":"e0218299","DOI":"10.1371\/journal.pone.0218299","article-title":"Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State, Brazil, 2000\u20132016","volume":"14","author":"M Bhering","year":"2019","journal-title":"PLoS One"},{"issue":"11","key":"pone.0250028.ref020","doi-asserted-by":"crossref","first-page":"e0218299","DOI":"10.1371\/journal.pone.0218299","article-title":"Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State, Brazil, 2000\u20132016","volume":"14","author":"M Bhering","year":"2019","journal-title":"PloS one"},{"issue":"1","key":"pone.0250028.ref021","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/s12879-017-2662-8","article-title":"Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China","volume":"17","author":"KA Alene","year":"2017","journal-title":"BMC infectious diseases"},{"issue":"6","key":"pone.0250028.ref022","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jiph.2019.04.009","article-title":"Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan","volume":"12","author":"I Khan","year":"2019","journal-title":"Journal of infection and public health"},{"issue":"1","key":"pone.0250028.ref023","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1038\/s41598-018-23344-z","article-title":"Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis","volume":"8","author":"JP Samuels","year":"2018","journal-title":"Scientific Reports"},{"key":"pone.0250028.ref024","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5588\/pha.17.0013","article-title":"Unfavourable outcomes among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India","volume":"7","author":"S Suryawanshi","year":"2017","journal-title":"Public Health Action"},{"key":"pone.0250028.ref025","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9241238","article-title":"Predictors for Mortality among Multidrug-Resistant Tuberculosis Patients in Tanzania","volume":"2017","author":"EW Mollel","year":"2017","journal-title":"J Trop Med"},{"key":"pone.0250028.ref026","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s12879-015-1214-3","article-title":"Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa","volume":"15","author":"T Umanah","year":"2015","journal-title":"BMC infectious diseases"},{"issue":"1","key":"pone.0250028.ref027","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09031936.00134712","article-title":"Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes","volume":"42","author":"D Falzon","year":"2013","journal-title":"European Respiratory Journal"},{"issue":"12","key":"pone.0250028.ref028","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.5588\/ijtld.18.0205","article-title":"Treatment outcomes of pre- and extensively drug-resistant tuberculosis in Johannesburg, South Africa","volume":"22","author":"J Nkurunziza","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"pone.0250028.ref029","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1183\/09031936.00028708","article-title":"Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases","volume":"31","author":"GB Migliori","year":"2008","journal-title":"European Respiratory Journal"},{"issue":"10150","key":"pone.0250028.ref030","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"N Ahmad","year":"2018","journal-title":"The Lancet"},{"issue":"1","key":"pone.0250028.ref031","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1186\/s12879-019-4189-7","article-title":"A nationwide study of multidrug-resistant tuberculosis in Portugal 2014\u20132017 using epidemiological and molecular clustering analyses","volume":"19","author":"O Oliveira","year":"2019","journal-title":"BMC infectious diseases"},{"issue":"1","key":"pone.0250028.ref032","doi-asserted-by":"crossref","first-page":"16646","DOI":"10.1038\/s41598-020-73759-w","article-title":"Using Bayesian spatial models to map and to identify geographical hotspots of multidrug-resistant tuberculosis in Portugal between 2000 and 2016","volume":"10","author":"O Oliveira","year":"2020","journal-title":"Sci Rep"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0250028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T17:49:23Z","timestamp":1618940963000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0250028"}},"subtitle":[],"editor":[{"given":"Sarman","family":"Singh","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0250028","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2021,4,20]]}}}